Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Fung

Showing results (61-70 of 199) with videos related to

Pageof 20
Sort By:
The American Journal of Gastroenterology|September 24, 2014
Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitisJames Fung, Danny Ka-Ho Wong, Wai-Kay Seto, et al.
Journal of Clinical Microbiology|December 22, 2021
Detection of the Hepatitis B Surface Antigen in Patients with Occult Hepatitis B by Use of an Assay with Enhanced SensitivityDanny Ka-Ho Wong, Claire Chen, Lung-Yi Mak, et al.
BMC Gastroenterology|March 18, 2021
First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patientsLung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, et al.
Cureus|June 13, 2025
Magnetic Resonance Imaging/Transrectal Ultrasound (MRI/TRUS) Fusion-Guided Prostate Biopsy: A Single-Center ExperienceSan Yu Leung, Kiujing James Fung, Wai Hung Lester Shiu, et al.
Expert Opinion on Drug Discovery|March 21, 2023
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkersLung-Yi Mak, Rex Wan-Hin Hui, Ka-Shing Cheung, et al.
The American Journal of Gastroenterology|May 21, 2009
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversionJames Fung, Ching-Lung Lai, Yasuhito Tanaka, et al.
Hepatology (Baltimore, Md.)|March 8, 2013
Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapyWai-Kay Seto, Danny Ka-Ho Wong, James Fung, et al.
Journal of Medical Virology|September 15, 2011
Stability of hepatitis B surface antigen over time: implications for studies using stored seraJames Fung, Ching-Lung Lai, John Young, et al.
The American Journal of Gastroenterology|July 12, 2008
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resectionIvan F N Hung, Ronnie T P Poon, Ching-Lung Lai, et al.
JHEP Reports : Innovation in Hepatology|May 29, 2020
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closedChing-Lung Lai, Danny Ka-Ho Wong, Gerald Tsz-Yau Wong, et al.
Pageof 20

Showing results (61-70 of 199) with videos related to

Sort By:
Pageof 20
The American Journal of Gastroenterology|September 24, 2014
Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitisJames Fung, Danny Ka-Ho Wong, Wai-Kay Seto, et al.
Journal of Clinical Microbiology|December 22, 2021
Detection of the Hepatitis B Surface Antigen in Patients with Occult Hepatitis B by Use of an Assay with Enhanced SensitivityDanny Ka-Ho Wong, Claire Chen, Lung-Yi Mak, et al.
BMC Gastroenterology|March 18, 2021
First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patientsLung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, et al.
Cureus|June 13, 2025
Magnetic Resonance Imaging/Transrectal Ultrasound (MRI/TRUS) Fusion-Guided Prostate Biopsy: A Single-Center ExperienceSan Yu Leung, Kiujing James Fung, Wai Hung Lester Shiu, et al.
Expert Opinion on Drug Discovery|March 21, 2023
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkersLung-Yi Mak, Rex Wan-Hin Hui, Ka-Shing Cheung, et al.
The American Journal of Gastroenterology|May 21, 2009
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversionJames Fung, Ching-Lung Lai, Yasuhito Tanaka, et al.
Hepatology (Baltimore, Md.)|March 8, 2013
Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapyWai-Kay Seto, Danny Ka-Ho Wong, James Fung, et al.
Journal of Medical Virology|September 15, 2011
Stability of hepatitis B surface antigen over time: implications for studies using stored seraJames Fung, Ching-Lung Lai, John Young, et al.
The American Journal of Gastroenterology|July 12, 2008
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resectionIvan F N Hung, Ronnie T P Poon, Ching-Lung Lai, et al.
JHEP Reports : Innovation in Hepatology|May 29, 2020
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closedChing-Lung Lai, Danny Ka-Ho Wong, Gerald Tsz-Yau Wong, et al.
Pageof 20